Le­gal ex­perts say some IRA chal­lenges are 'weak­er than oth­er­s'

Drug­mak­ers have cit­ed a range of con­sti­tu­tion­al chal­lenges in their broad fight to block the Medicare ne­go­ti­a­tion pro­vi­sions of the In­fla­tion Re­duc­tion Act, some of which “are weak­er than oth­ers,” ac­cord­ing to le­gal ex­perts.

The new law re­quires drug­mak­ers to par­tic­i­pate in Medicare price ne­go­ti­a­tions, or else pay a steep fine or risk los­ing Medicare and Med­ic­aid cov­er­age for their ther­a­pies. Mer­ck was the first to sue the fed­er­al gov­ern­ment in June, fol­lowed by a hand­ful of oth­er man­u­fac­tur­ers, PhRMA and the Cham­ber of Com­merce. The ar­gu­ments have said the IRA vi­o­lates sev­er­al amend­ments by com­pelling the com­pa­nies’ speech, im­pos­ing ex­ces­sive fines, tak­ing pri­vate prop­er­ty with­out due process and fair com­pen­sa­tion, and more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER